MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company DPO Ratio 2011-2026 | LLY
Annual DPO Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 | 126 | 117 | 99.1 | 81.8 | 100 | 109 | 80.2 | 84.8 | 87.1 | 97 | 83.5 | 83.2 | 90.4 | 81 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 142 | 80.2 | 97.5 |
Quarterly DPO Ratio Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 140 | 130 | 122 | 113 | 134 | 120 | 113 | 111 | - | 48.6 | 45.7 | 68.3 | - | 101 | 75.6 | 78.8 | - | 111 | 120 | 113 | 100 | 109 | 114 | 105 | 97.5 | 95.5 | 89.2 | 94.6 | 101 | 111 | 113 | 131 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 140 | 45.7 | 104 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55 | $ 323.44 | -2.98 % | $ 42.4 B | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 21.93 | 1.15 % | $ 1.03 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Akebia Therapeutics
AKBA
|
168 | $ 1.38 | -10.97 % | $ 355 M | USA |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.22 | -0.59 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.83 | -3.05 % | $ 3.03 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.54 | 3.02 % | $ 410 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
51.2 | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
1.67 K | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
4.06 K | $ 33.61 | -0.77 % | $ 2.23 B | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |